Effects of canagliflozin on liver steatosis and fibrosis markers in patients with type 2 diabetes and chronic kidney disease: A post hoc analysis of the CREDENCE trial. Issue 5 (6th February 2023) - Koshino, Akihiko; Oshima, Megumi; Arnott, Clare; Fletcher, Robert A.; Bakris, George L.; Jardine, Meg; Mahaffey, Kenneth W.; Perkovic, Vlado; Pollock, Carol; Heerspink, Hiddo J. L.; Neuen, Brendon L.